Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients

被引：6
|
作者：
Zhu, Huaijun [1 ]
Ge, Weihong [1 ]
机构：
[1] Nanjing Univ, Affiliated Nanjing Drum Tower Hosp, Sch Med, Dept Pharm, Nanjing 210008, Jiangsu, Peoples R China
来源：
PHARMACOGENOMICS | 2011年 / 12卷 / 11期
关键词：
calcineurin inhibitor; epigenetics; orphan nuclear receptor; pharmacogenomics; renal transplantation; REGULATED GENE-EXPRESSION; RECIPIENTS; THERAPY; PHARMACOKINETICS; PHARMACODYNAMICS; PERSPECTIVES; CELLS; CYP3A;
D O I：
10.2217/PGS.11.129
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1505 / 1508
页数：4
相关论文
共 50 条
  • [1] The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients
    Sahin, G.
    Akay, O. M.
    Bal, C.
    Yalcin, A. U.
    Gulbas, Z.
    CLINICAL NEPHROLOGY, 2011, 76 (03) : 218 - 225
  • [2] Calcineurin inhibitors in pediatric renal transplant recipients
    Filler G.
    Pediatric Drugs, 2007, 9 (3) : 165 - 174
  • [3] Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients
    Albring, Antje
    Wendt, Laura
    Harz, Nino
    Engler, Harald
    Wilde, Benjamin
    Kribben, Andreas
    Lindemann, Monika
    Schedlowski, Manfred
    Witzke, Oliver
    CLINICAL TRANSPLANTATION, 2015, 29 (04) : 294 - 300
  • [4] Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis
    Cornu, Catherine
    Dufays, Christophe
    Gaillard, Segolene
    Gueyffier, Francois
    Redonnet, Michel
    Sebbag, Laurent
    Roussoulieres, Ana
    Gleissner, Christian A.
    Groetzner, Jan
    Lehmkuhl, Hans B.
    Potena, Luciano
    Gullestad, Lars
    Cantarovich, Marcelo
    Boissonnat, Pascale
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (01) : 24 - 32
  • [5] Insulin Requirement After a Renal Transplant in Patients With Type 2 Diabetes: The Choice of Calcineurin Inhibitors
    van den Hoogen, Martijn W. F.
    van der Hoeven, Anna M.
    Hilbrands, Luuk B.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2013, 11 (03) : 234 - 238
  • [6] Results of 4-Year Analysis of Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplant Patients: Single-Center Experience
    Sert, Mehmet
    Celik, Ali
    Kural, Kemal
    Ersan, Sibel
    Ataca, Pinar
    Atila, Koray
    Cavdar, Caner
    Sifil, Aykut
    Bora, Seymen
    Gulay, Huseyin
    Camsari, Taner
    RENAL FAILURE, 2011, 33 (08) : 789 - 794
  • [7] Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant patients
    Ciftci H.S.
    Ayna T.K.
    Calıskan Y.K.
    Turkmen A.
    Gurtekin M.
    Indian Journal of Clinical Biochemistry, 2013, 28 (2) : 164 - 168
  • [8] Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients
    Martinez-Mier, Gustavo
    Avila-Pardo, Sandro F.
    Mendez-Lopez, Marco T.
    Budar-Fernandez, Luis F.
    CLINICAL TRANSPLANTATION, 2010, 24 (04) : 467 - 473
  • [9] Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors
    San Millan, Juan Carlos Ruiz
    Lopez-Hoyos, Marcos
    San Segundo, David
    Quintela, Estrella
    Rodrigo, Emilio
    Gomez-Alamillo, Carlos
    Romon, Inigo
    Arias, Manuel
    TRANSPLANT INTERNATIONAL, 2014, 27 (08) : 847 - 856
  • [10] The effect of calcineurin inhibitors on endothelial function in renal transplant recipients
    Oflaz, H
    Turkmen, A
    Kazancioglu, R
    Kayacan, SM
    Bunyak, B
    Genchallac, H
    Erol, B
    Mercanoglu, F
    Umman, S
    Sever, MS
    CLINICAL TRANSPLANTATION, 2003, 17 (03) : 212 - 216
12345